Retinitis and optic neuritis in a child with chickenpox: case report and review of literature

In immunocompetent individuals, necrotizing retinopathy is a rare complication of chickenpox. Herein, we report on a 3-year-old immunocompetent boy who developed retinitis and optic neuritis 3 days after the onset of chickenpox and compare the findings to published cases. Since macula and optic nerve were affected, visual acuity remained poor. An early diagnosis and treatment of ocular manifestations in chickenpox is imperative for the preservation of a residual visual function and prevention of blinding secondary complications.

Transient raise of endothelin-1 plasma level and reduction of ocular blood flow in a patient with optic neuritis

PURPOSE: To analyze how far an ischemic component might have been involved in optic neuritis. METHODS: Case report: a 32-year-old man with symptoms characteristic for optic neuritis underwent extensive clinical, laboratory/serological and vascular examination for systemic associations and vascular involvement. RESULTS: The patient was found to have a temporary ocular blood flow dysregulation and increased plasma endothelin-1 levels which decreased after the acute phase of the optic nerve. CONCLUSIONS: We conclude that there might be an ischemic component in this patient with optic neuritis and hypothesize that this ischemic component is at least in part due to a temporarily increased endothelin-1 level.

HIV-assoziierte Neuritis des Nervus vestibulocochlearis. Fallbeschreibung und systematische Literaturanalyse der HIV-assoziierten Polyneuropathien

Die Polyneuropathien sind Komplikationen der Infektion mit dem Human- Immunodeficiency-Virus (HIV). Dazu gehören Polyradikulopathien, distale (sensible) Polyneuropathien, Mono- und Oligoneuropathien und brachiale Neuritiden. Selten gibt es Formen, die sich nicht kategorisieren lassen. In dieser Dissertation präsentieren wir einen aussergewöhnlichen Fall einer bilateralen Neuritis des Nervus vestibulo-cochlearis (N. vestibulocochlearis). In einer ausgedehnten Literaturrecherche ist das erst der dritte beschriebene Fall. Gleichzeitig wurde die Literaturrecherche genutzt, um epidemiologische, klinische und laborchemische Parameter der HIV-assoziierten Polyneuropathien zu analysieren. Dazu wurden Daten von 539 Patientinnen aus 67 Publikationen extrahiert und ausgewertet. Die Daten wurden bezüglich ihrer Qualität gewertet, um den Schlussfolgerungen eine Gewichtung zu geben. Die Literaturanalyse ergab, dass die meisten Daten zu HIVassoziierten – und bezüglich antiretroviraler Therapie (ART) naiven – Polyneuropathien von afrikanischen Patienten stammen. Die meisten europäischen und nordamerikanischen Studien zu diesem Thema wurden vor 1996 publiziert. Polyradikulopathien präsentieren sich typischerweise früh und distale (sensible) Polyneuropathien spät in der HIV-Krankheit. Das Guillain-Barré-Syndrom war das häufigste Krankheitsbild der Polyradikulopathien. Die häufigste Präsentation distaler Polyneuropathien sind Sensibilitätsausfälle an den unteren Extremitäten. Bei den Mono- und Oligoneuropathien hat ein Grossteil der Personen Mononeuropathien, wobei der N. facialis am häufigsten betroffen ist. Die Rolle der ART zur Erholung der Neuropathien konnte nicht beurteilt werden. Unter den HIV-assoziierten Polyneuropathien haben die distalen (sensiblen) Polyneuropathien die schlechtere und die Polyradikulopathien und Mono- oder Oligoneuropathien die bessere Prognose bezüglich Erholung

VOR gain by head impulse video-oculography differentiates acute vestibular neuritis from stroke

OBJECTIVE Vestibular neuritis is often mimicked by stroke (pseudoneuritis). Vestibular eye movements help discriminate the two conditions. We report vestibulo-ocular reflex (VOR) gain measures in neuritis and stroke presenting acute vestibular syndrome (AVS). METHODS Prospective cross-sectional study of AVS (acute continuous vertigo/dizziness lasting >24 h) at two academic centers. We measured horizontal head impulse test (HIT) VOR gains in 26 AVS patients using a video HIT device (ICS Impulse). All patients were assessed within 1 week of symptom onset. Diagnoses were confirmed by clinical examinations, brain magnetic resonance imaging with diffusion-weighted images, and follow-up. Brainstem and cerebellar strokes were classified by vascular territory-posterior inferior cerebellar artery (PICA) or anterior inferior cerebellar artery (AICA). RESULTS Diagnoses were vestibular neuritis (n = 16) and posterior fossa stroke (PICA, n = 7; AICA, n = 3). Mean HIT VOR gains (ipsilesional [standard error of the mean], contralesional [standard error of the mean]) were as follows: vestibular neuritis (0.52 [0.04], 0.87 [0.04]); PICA stroke (0.94 [0.04], 0.93 [0.04]); AICA stroke (0.84 [0.10], 0.74 [0.10]). VOR gains were asymmetric in neuritis (unilateral vestibulopathy) and symmetric in PICA stroke (bilaterally normal VOR), whereas gains in AICA stroke were heterogeneous (asymmetric, bilaterally low, or normal). In vestibular neuritis, borderline gains ranged from 0.62 to 0.73. Twenty patients (12 neuritis, six PICA strokes, two AICA strokes) had at least five interpretable HIT trials (for both ears), allowing an appropriate classification based on mean VOR gains per ear. Classifying AVS patients with bilateral VOR mean gains of 0.70 or more as suspected strokes yielded a total diagnostic accuracy of 90%, with stroke sensitivity of 88% and specificity of 92%. CONCLUSION Video HIT VOR gains differ between peripheral and central causes of AVS. PICA strokes were readily separated from neuritis using gain measures, but AICA strokes were at risk of being misclassified based on VOR gain alone.

Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol.

INTRODUCTION Optic neuritis leads to degeneration of retinal ganglion cells whose axons form the optic nerve. The standard treatment is a methylprednisolone pulse therapy. This treatment slightly shortens the time of recovery but does not prevent neurodegeneration and persistent visual impairment. In a phase II trial performed in preparation of this study, we have shown that erythropoietin protects global retinal nerve fibre layer thickness (RNFLT-G) in acute optic neuritis; however, the preparatory trial was not powered to show effects on visual function. METHODS AND ANALYSIS Treatment of Optic Neuritis with Erythropoietin (TONE) is a national, randomised, double-blind, placebo-controlled, multicentre trial with two parallel arms. The primary objective is to determine the efficacy of erythropoietin compared to placebo given add-on to methylprednisolone as assessed by measurements of RNFLT-G and low-contrast visual acuity in the affected eye 6 months after randomisation. Inclusion criteria are a first episode of optic neuritis with decreased visual acuity to ≤0.5 (decimal system) and an onset of symptoms within 10 days prior to inclusion. The most important exclusion criteria are history of optic neuritis or multiple sclerosis or any ocular disease (affected or non-affected eye), significant hyperopia, myopia or astigmatism, elevated blood pressure, thrombotic events or malignancy. After randomisation, patients either receive 33 000 international units human recombinant erythropoietin intravenously for 3 consecutive days or placebo (0.9% saline) administered intravenously. With an estimated power of 80%, the calculated sample size is 100 patients. The trial started in September 2014 with a planned recruitment period of 30 months. ETHICS AND DISSEMINATION TONE has been approved by the Central Ethics Commission in Freiburg (194/14) and the German Federal Institute for Drugs and Medical Devices (61-3910-4039831). It complies with the Declaration of Helsinki, local laws and ICH-GCP. TRIAL REGISTRATION NUMBER NCT01962571.